Among them, GSK2816126 is characterized by high and selective biochemical and cellular on-target potency, assessed by decrease in H3K27 trimethylation levels, has been validated in preclinical studies for treatment of lymphoma with EZH2-activating mutations [21], and is actually in phase I clinical trial for the treatment of lymphomas, solid tumors and multiple myeloma (https://clinicaltrials.gov/ct2/results?term=GSK2816126&Search=Search). This evidence concerns the gene EZH2 and lymphoma.